✨ Medicines and Mental Health Notices
20 OCTOBER 2005
NEW ZEALAND GAZETTE, No. 177
4501
Product:
Lipitor
Active Ingredient:
Atorvastatin calcium 10.85mg equivalent to 10mg atorvastatin
Dosage Form:
Film coated tablet
New Zealand Sponsor:
Pfizer New Zealand Limited
Manufacturers:
Godecke GmbH, Freiburg, Germany
Parke Davis Pharmaceuticals Limited, Vega Baja, Puerto Rico
Parke-Davis, Usine Pharmaceutique d’Angers, France
Pfizer Ireland Pharmaceuticals, Ringaskiddy, County Cork, Ireland
Warner-Lambert Company, Lititz, Pennsylvania, United States of America
Product:
Lipitor
Active Ingredient:
Atorvastatin calcium 21.69mg equivalent to 20mg atorvastatin
Dosage Form:
Film coated tablet
New Zealand Sponsor:
Pfizer New Zealand Limited
Manufacturers:
Godecke GmbH, Freiburg, Germany
Parke Davis Pharmaceuticals Limited, Vega Baja, Puerto Rico
Parke-Davis, Usine Pharmaceutique d’Angers, France
Pfizer Ireland Pharmaceuticals, Ringaskiddy, County Cork, Ireland
Warner-Lambert Company, Lititz, Pennsylvania, United States of America
Product:
Lipitor
Active Ingredient:
Atorvastatin calcium 43.38mg equivalent to 40mg atorvastatin
Dosage Form:
Film coated tablet
New Zealand Sponsor:
Pfizer New Zealand Limited
Manufacturers:
Godecke GmbH, Freiburg, Germany
Parke Davis Pharmaceuticals Limited, Vega Baja, Puerto Rico
Parke-Davis, Usine Pharmaceutique d’Angers, France
Pfizer Ireland Pharmaceuticals, Ringaskiddy, County Cork, Ireland
Warner-Lambert Company, Lititz, Pennsylvania, United States of America
Product:
Lipitor
Active Ingredient:
Atorvastatin calcium 86.76mg equivalent to 80mg atorvastatin
Dosage Form:
Film coated tablet
New Zealand Sponsor:
Pfizer New Zealand Limited
Manufacturer:
Parke Davis Pharmaceuticals Limited, Vega Baja, Puerto Rico
Product:
Lucrin Depot 1-month
Active Ingredient:
Leuprorelin acetate 3.75mg
Dosage Form:
Powder for injection
New Zealand Sponsor:
Abbott Laboratories (NZ) Limited
Manufacturer:
Takeda Chemical Industries Limited, Fugisawa-shi, Japan
Product:
Lucrin Depot 3-month
Active Ingredient:
Leuprorelin acetate 11.25mg
Dosage Form:
Powder for injection
New Zealand Sponsor:
Abbott Laboratories (NZ) Limited
Manufacturer:
Takeda Chemical Industries Limited, Fugisawa-shi, Japan
Dated this 12th day of October 2005.
DON MATHESON, Deputy Director-General, Public Health (pursuant to delegation given by the Minister of Health on 6 July 2001).
go6929
Mental Health (Compulsory Assessment and Treatment) Act 1992
Mental Health (Compulsory Assessment and Treatment) Act Notice 2005—Appointment of Directors of Area Mental Health Services
Pursuant to section 92 of the Mental Health (Compulsory Assessment and Treatment) Act 1992, I, Karen Olive Poutasi, Director-General of Health, give the following notice.
-
This notice shall be read together with the Mental Health (Compulsory Assessment and Treatment) Act Notice 2000—Appointment of Directors of Area Mental Health Services ("the principal notice").
-
The Schedule to the principal notice is amended in respect of
"Area 9—Wellington"
by including the name and title
"Dr Zarko Kamenica, consultant psychiatrist, of Masterton".
Dated at Wellington this 17th day of October 2005.
KAREN O. POUTASI (DR), Director-General of Health.
New Zealand Gazette, 31 August 2000, page 2963
go7070
Next Page →
Online Sources for this page:
VUW Te Waharoa —
NZ Gazette 2005, No 177
Gazette.govt.nz —
NZ Gazette 2005, No 177
✨ LLM interpretation of page content
🏥 Consent to Distribution of Lipitor
🏥 Health & Social Welfare12 October 2005
Medicines, Consent, Lipitor, Atorvastatin calcium
- DON MATHESON, Deputy Director-General, Public Health
🏥 Consent to Distribution of Lucrin Depot
🏥 Health & Social Welfare12 October 2005
Medicines, Consent, Lucrin Depot, Leuprorelin acetate
- DON MATHESON, Deputy Director-General, Public Health
🏥 Appointment of Directors of Area Mental Health Services
🏥 Health & Social Welfare17 October 2005
Mental Health, Appointment, Directors, Wellington
- Zarko Kamenica (Dr), Appointed Director of Area Mental Health Services
- KAREN O. POUTASI (DR), Director-General of Health